Depo-Medrol and myelographic arachnoiditis

Area of Science:

• Neurology
• Pharmacology
• Radiology

Background:

• Arachnoiditis is a condition affecting the arachnoid mater, a membrane surrounding the brain and spinal cord.
• Methylprednisolone acetate (Depo-Medrol) is a corticosteroid medication sometimes implicated in neurological adverse events.

Purpose of the Study:

• To determine if patients with a radiological diagnosis of arachnoiditis caused by methylprednisolone acetate (Depo-Medrol) exhibited the clinical syndrome of arachnoiditis.
• To assess the correlation between radiological findings and clinical presentation of corticosteroid-induced arachnoiditis.

Main Methods:

• Review of patients previously reported with radiological diagnosis of corticosteroid-induced arachnoiditis.
• Detailed clinical history and physical examinations were conducted.
• 15 out of 18 identified patients participated in the study.

Main Results:

• The clinical syndrome of arachnoiditis was characterized by severe pain, neurological deficits, and functional limitations.
• Only 3 of the 15 patients studied presented with the defined clinical syndrome.
• No clear relationship was found between the severity of radiological changes and symptom intensity.

Conclusions:

• The findings suggest a potential link between methylprednisolone acetate (Depo-Medrol) and arachnoiditis.
• The study recommends against the use of Depo-Medrol in or around the thecal sac due to the risk of arachnoiditis.
• Further investigation is warranted to fully understand the risk-benefit profile of Depo-Medrol in specific anatomical locations.